InvestorsObserver
×
News Home

Is Rocket Pharmaceuticals Inc (RCKT) Stock a Good Value Monday?

Monday, November 20, 2023 12:15 PM | InvestorsObserver Analysts

Mentioned in this article

Is Rocket Pharmaceuticals Inc (RCKT) Stock a Good Value Monday?

Rocket Pharmaceuticals Inc (RCKT) is near the top in its sector according to InvestorsObserver. RCKT gets an overall rating of 78. That means it scores higher than 78% of stocks. Rocket Pharmaceuticals Inc gets a 99 rank in the Healthcare sector. Healthcare is number 4 out of 11 sectors.

Overall Score - 78
RCKT has an Overall Score of 78. Find out what this means to you and get the rest of the rankings on RCKT!

What do These Ratings Mean?

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. *Investors Observer* makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts. These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

What's Happening With Rocket Pharmaceuticals Inc Stock Today?

Rocket Pharmaceuticals Inc (RCKT) stock is trading at $22.00 as of 12:12 PM on Monday, Nov 20, an increase of $0.05, or 0.23% from the previous closing price of $21.95. Volume today is below average. So far 251,059 shares have traded compared to average volume of 867,504 shares. The stock has traded between $21.89 and $22.75 so far today. Click Here to get the full Stock Report for Rocket Pharmaceuticals Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App